Naftopidil

萘哌地尔

Report date: 2022/03/30 13:41:44
NME

Base Information

Drug NameNaftopidil
Drug Alias Name萘呱地尔NaphtopidilFlivasAvishotEapidil +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptor alpha-1 antagonists
TargetsAdrenergic receptors alpha-1
Therapy Area/IndicationsDysuriaHyperplasiaProstatic Hyperplasia
Global Approved IndicationsDysuriaProstatic Hyperplasia
Approved Indications in ChinaDysuriaProstatic Hyperplasia
Original Approved Country/TerritoryJapan
Original Approved Date1998/12/25
Country/TerritoryBrazilSouth KoreaMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHongkong WinHealth Pharma Group Co LtdGuizhou-Eakan Pharmaceutical Co Ltd
Inactive CompaniesApsen Farmaceutica S/ADong-A ST Co Ltd
Active IndicationsDysuriaProstatic Hyperplasia
Inactive IndicationsHyperplasia

Other Information

ATC CodeG04CA
Related LinksWikipediaKEGG